Download PDF

1. Company Snapshot

1.a. Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.


It also has a manufacturing agreement with Samsung Biologics Co.,Ltd.for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc.for chronic hepatitis B virus.


Vir Biotechnology, Inc.was incorporated in 2016 and is headquartered in San Francisco, California.

Show Full description

1.b. Last Insights on VIR

Vir Biotechnology's recent performance was driven by positive developments in its clinical portfolio. The company completed enrollment in its ECLIPSE 1 Phase 3 trial for chronic hepatitis delta, evaluating the combination of tobevibart and elebsiran. Additionally, Vir announced positive Week 48 endpoint results from the SOLSTICE Phase 2 clinical study, demonstrating high rates of undetectable HDV RNA with a favorable safety profile. The company also dosed the first patient in Part 3 of its Phase 1 trial of VIR-5500 for metastatic prostate cancer.

1.c. Company Highlights

2. Vir Biotechnology's Q3 2025 Earnings: A Closer Look

The company's net loss for the third quarter of 2025 was $163.1 million, compared to a net loss of $213.7 million for the same period last year. The earnings per share (EPS) came out at -$1.17, missing analyst estimates of -$0.7. Research and development (R&D) expenses were $151.5 million, down from $195.2 million in the same quarter last year, driven by a decrease in milestone payments and upfront fees.

Publication Date: Nov -21

📋 Highlights
  • HDV Enrollment Completed: ECLIPSE 1 Phase III trial for hepatitis delta enrolled ~120 patients (2:1 ratio) 2 months ahead of schedule.
  • Cash Reserves Extended: $810.7M cash and investments, with runway projected through mid-2027.
  • VIR-5500 Data Milestone: Comprehensive update planned Q1 2026, including safety, PSA responses, and imaging data across dose levels.
  • Reduced Net Loss: Q3 2025 net loss decreased to $163.1M vs. $213.7M in Q3 2024.

Financial Performance

The company's cash, cash equivalents, and investments stood at approximately $810.7 million at the end of the third quarter, providing a cash runway into mid-2027. The current operating plan is expected to support the advancement of the registrational hepatitis delta program and the oncology pipeline.

Clinical Development Programs

Vir Biotechnology made significant progress in its clinical development programs during the quarter. The company completed enrollment in the ECLIPSE 1 study, a registrational Phase III trial for hepatitis delta, and dosed the first patient in a first-line metastatic castration-resistant prostate cancer combination study with androgen receptor pathway inhibitors. The VIR-5500 program, a masked PSMA-targeted T-cell engager, is advancing with dose escalation in both weekly and every 3-week schedules.

Valuation Metrics

With a Price-to-Sales Ratio of 46.41, the market is pricing in significant revenue growth, which is expected to reach 49.8% next year according to analyst estimates. The company's Return on Equity (ROE) and Return on Invested Capital (ROIC) are negative, at -50.22% and -54.59%, respectively, indicating that the company is still in investment mode. The current valuation multiples suggest that the market is expecting a significant turnaround in the company's financial performance.

Future Outlook

The company is expected to share a comprehensive data update for VIR-5500 in the first quarter of 2026, which will provide important insights into the program's potential. The data will include safety assessments, efficacy measures, and imaging and RECIST evaluations. The company's strong financial foundation and progress in its clinical development programs position it for significant value-creating opportunities ahead.

3. NewsRoom

Card image cap

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Nov -19

Source: businesswire.com

Card image cap

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Nov -09

Source: businesswire.com

Card image cap

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Nov -07

Source: businesswire.com

Card image cap

Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript

Nov -06

Source: seekingalpha.com

Card image cap

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Nov -05

Source: zacks.com

Card image cap

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov -05

Source: businesswire.com

Card image cap

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Nov -03

Source: businesswire.com

Card image cap

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct -22

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.95%)

6. Segments

Antibody-based Therapies

Expected Growth: 9.95%

Vir Biotechnology's antibody-based therapies exhibit strong growth driven by increasing demand for effective treatments of infectious diseases, strategic partnerships, and a robust pipeline of novel candidates. The company's focus on addressing high-unmet medical needs, coupled with its expertise in antibody discovery and development, fuels growth. Additionally, the rising prevalence of diseases such as hepatitis B and COVID-19 contributes to the segment's 9.95% growth.

7. Detailed Products

Sotrovimab

A monoclonal antibody for the treatment of COVID-19

VIR-3434

An HBV-neutralizing monoclonal antibody for the treatment of Hepatitis B

VIR-2218

A small interfering RNA (siRNA) for the treatment of Hepatitis B

VIR-2482

A monoclonal antibody for the treatment of Influenza A

VIR-3431

A monoclonal antibody for the treatment of HIV

8. Vir Biotechnology, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Vir Biotechnology, Inc. is medium due to the presence of alternative treatments and therapies for infectious diseases. While the company's products may have some unique features, they are not entirely irreplaceable.

Bargaining Power Of Customers

The bargaining power of customers is low for Vir Biotechnology, Inc. as the company's products are primarily sold to healthcare providers and governments, which have limited negotiating power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium for Vir Biotechnology, Inc. as the company relies on a few key suppliers for raw materials and manufacturing services. While the company has some negotiating power, suppliers may still have some leverage.

Threat Of New Entrants

The threat of new entrants is high for Vir Biotechnology, Inc. as the biotechnology industry is highly competitive and attractive to new entrants. The company's intellectual property and regulatory approvals may provide some barriers to entry, but new entrants may still be able to enter the market.

Intensity Of Rivalry

The intensity of rivalry is high for Vir Biotechnology, Inc. as the company operates in a highly competitive industry with many established players. The company must continually innovate and differentiate its products to maintain market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 7.26%
Debt Cost 3.95%
Equity Weight 92.74%
Equity Cost 6.24%
WACC 6.07%
Leverage 7.83%

11. Quality Control: Vir Biotechnology, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Seer

A-Score: 4.5/10

Value: 8.0

Growth: 4.2

Quality: 4.6

Yield: 0.0

Momentum: 6.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
2seventy bio

A-Score: 3.7/10

Value: 7.6

Growth: 4.4

Quality: 4.4

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
OncoCyte

A-Score: 3.7/10

Value: 7.0

Growth: 6.0

Quality: 3.2

Yield: 0.0

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Curis

A-Score: 3.6/10

Value: 9.2

Growth: 3.9

Quality: 6.0

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Vir Biotechnology

A-Score: 3.3/10

Value: 7.6

Growth: 3.6

Quality: 5.0

Yield: 0.0

Momentum: 2.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Pliant Therapeutics

A-Score: 2.6/10

Value: 7.8

Growth: 3.2

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.78$

Current Price

6.78$

Potential

-0.00%

Expected Cash-Flows